The utility of pretreatment systemic inflammatory response biomarkers on overall survival of cervical cancer patients stratified by clinical staging

Current evidence supports the theory that inflammation plays a key role in the initiation and progression of many cancers. Systemic inflammation can influence carcinogenesis and tumor evolution, possibly by increasing the inflammatory cytokines which in turn contributes to an environment that promotes tumor development and progression [1,2]. The role of indexes based on nonspecific systemic inflammatory markers such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and derived neutrophil-lymphocyte ratio (dNLR) has been widely studied in different cancer types [3].